Hunter L. Mathews
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Hunter L. Mathews has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Aaron John Gorelik
Department of Psychological and Brain Sciences, Washington University in St. Louis, St. Louis, MO, USA
1 shared publication - Alex P. Miller
Department of Psychiatry Indiana University School of Medicine Indianapolis Indiana USA
1 shared publication - Alexander S. Hatoum
Washington University School of Medicine
1 shared publication Arpana Agrawal
Department of Psychiatry Washington University School of Medicine St. Louis Missouri USA
1 shared publicationDavid A. A. Baranger
Department of Pharmacology and Toxicology Medical College of Wisconsin Milwaukee Wisconsin USA
1 shared publication- Emma C. Johnson
Department of Psychiatry Washington University School of Medicine St. Louis Missouri USA
1 shared publication
Latest Publications
- 7 September 2026
- Published by Wiley in Alcohol, Clinical and Experimental Research
- Vol. 50 (9) , e70364
Classification of Alcohol Use Disorder With Explainable AI
Background: The wide‐ranging correlates (e.g., demographic, socioeconomic status [SES], brain, genetics) of alcohol use disorder (AUD) are typically characterized by small effects and studied in isolation. Novel multivariable nonlinear approaches may help characterize the multifaceted correlates of AUD and identify its strongest predictors. Method: Here, using Gradient Boosted Machines (GBMs), we classify AUD in the UK Biobank ( N = 12,178) from features ( n = 440) within the following 5 domains: (1) demographic ( n = 12), (2) socioeconomic status ( n = 18), (3) non‐substance mental health ( n = 55), (4) non‐alcohol substance involvement ( n = 6), and (5) biological features ( n = 342). We use Explainable Artificial Intelligence (xAI) to characterize each respective feature's contribution to model performance and its heterogeneity, as well as the extent to which features from each domain collectively contribute to model performance. Results: In an out‐of‐sample hold‐out test set ( n = 6089), our model classified lifetime AUD well (AUC = 0.80). Notably, feature importance analyses revealed that demographic (age, sex, income), substance use (ever smoke tobacco or ever use cannabis), and mental health questionnaires (social isolation) were most informative to classifying AUD. The gradient boosted machine significantly outperformed a linear model and implicated non‐zero pairwise interactions among variables, suggesting potential heterogeneity of AUD presentation by income and sex. Further, incrementally incorporating neuroimaging and genetic data as features led to small but consistent improvement in classifying AUD, with small effect sizes distributed across a number of variables (0%–2% gain based on overall model classification). This suggests the continued importance of biological features in classifying AUD beyond psychological and demographic measures, though classification with single selected brain regions may be limited. Conclusion: Multimodal multivariable approaches considering nonlinear relationships may improve our understanding of AUD correlates. Particularly, accounting for interactions with demographic factors and integrating information across biological features may enhance model performance.
- 7 September 2026
- Published by Wiley in Alcohol, Clinical and Experimental Research
- Vol. 50 (9) , e70364
Classification of Alcohol Use Disorder With Explainable AI
Background: The wide‐ranging correlates (e.g., demographic, socioeconomic status [SES], brain, genetics) of alcohol use disorder (AUD) are typically characterized by small effects and studied in isolation. Novel multivariable nonlinear approaches may help characterize the multifaceted correlates of AUD and identify its strongest predictors. Method: Here, using Gradient Boosted Machines (GBMs), we classify AUD in the UK Biobank ( N = 12,178) from features ( n = 440) within the following 5 domains: (1) demographic ( n = 12), (2) socioeconomic status ( n = 18), (3) non‐substance mental health ( n = 55), (4) non‐alcohol substance involvement ( n = 6), and (5) biological features ( n = 342). We use Explainable Artificial Intelligence (xAI) to characterize each respective feature's contribution to model performance and its heterogeneity, as well as the extent to which features from each domain collectively contribute to model performance. Results: In an out‐of‐sample hold‐out test set ( n = 6089), our model classified lifetime AUD well (AUC = 0.80). Notably, feature importance analyses revealed that demographic (age, sex, income), substance use (ever smoke tobacco or ever use cannabis), and mental health questionnaires (social isolation) were most informative to classifying AUD. The gradient boosted machine significantly outperformed a linear model and implicated non‐zero pairwise interactions among variables, suggesting potential heterogeneity of AUD presentation by income and sex. Further, incrementally incorporating neuroimaging and genetic data as features led to small but consistent improvement in classifying AUD, with small effect sizes distributed across a number of variables (0%–2% gain based on overall model classification). This suggests the continued importance of biological features in classifying AUD beyond psychological and demographic measures, though classification with single selected brain regions may be limited. Conclusion: Multimodal multivariable approaches considering nonlinear relationships may improve our understanding of AUD correlates. Particularly, accounting for interactions with demographic factors and integrating information across biological features may enhance model performance.
- 18 December 2018
- Published by Springer Nature in Psychopharmacology
- Vol. 236 (4) , 1335-1347
The effects of oral nicotine administration and abstinence on sleep in male C57BL/6J mice
Background Sleep disturbances are common in smoking cessation attempts and are predictive of relapse. Despite this knowledge, there is no established animal model to study the effect of nicotine abstinence on sleep and EEG parameters. Objectives The present study was conducted to characterize sleep and wakefulness in male C57BL/6J mice during periods of oral nicotine administration and abstinence. Methods Male C57BL/6J mice were implanted with EEG/EMG recording devices. EEG/EMG data were recorded continuously for a period of 4 weeks. At the beginning of week 2, 200 μg/ml of nicotine was added to the 0.2% saccharin vehicle drinking solution. Following a 2-week period of oral nicotine administration, abstinence was initiated by excluding the nicotine from the 0.2% saccharin vehicle drinking solution. EEG/EMG were analyzed at pre-nicotine baseline, during nicotine administration, and on days 1, 2, and 5 of abstinence from nicotine. Results Oral nicotine administration decreased total sleep time during the active phase, consistent with the stimulant actions of nicotine. In contrast, NREM sleep quantity was increased during the active phase on nicotine abstinence day 1 and REM sleep was decreased during days 2 and 5 of abstinence. Further, sleep fragmentation was increased during the inactive phase on all days of abstinence. Oral nicotine administration and abstinence from nicotine also altered EEG relative power frequencies during the inactive and active phase. Conclusions Both oral nicotine administration and abstinence lead to sleep disturbances in mice. Similarities between this model and human reports on the effect of nicotine/nicotine withdrawal on sleep support its utility in examining the molecular mechanisms that modulate the relationship between sleep, nicotine, and nicotine abstinence/withdrawal.
- 18 December 2018
- Published by Springer Nature in Psychopharmacology
- Vol. 236 (4) , 1335-1347
The effects of oral nicotine administration and abstinence on sleep in male C57BL/6J mice
Background Sleep disturbances are common in smoking cessation attempts and are predictive of relapse. Despite this knowledge, there is no established animal model to study the effect of nicotine abstinence on sleep and EEG parameters. Objectives The present study was conducted to characterize sleep and wakefulness in male C57BL/6J mice during periods of oral nicotine administration and abstinence. Methods Male C57BL/6J mice were implanted with EEG/EMG recording devices. EEG/EMG data were recorded continuously for a period of 4 weeks. At the beginning of week 2, 200 μg/ml of nicotine was added to the 0.2% saccharin vehicle drinking solution. Following a 2-week period of oral nicotine administration, abstinence was initiated by excluding the nicotine from the 0.2% saccharin vehicle drinking solution. EEG/EMG were analyzed at pre-nicotine baseline, during nicotine administration, and on days 1, 2, and 5 of abstinence from nicotine. Results Oral nicotine administration decreased total sleep time during the active phase, consistent with the stimulant actions of nicotine. In contrast, NREM sleep quantity was increased during the active phase on nicotine abstinence day 1 and REM sleep was decreased during days 2 and 5 of abstinence. Further, sleep fragmentation was increased during the inactive phase on all days of abstinence. Oral nicotine administration and abstinence from nicotine also altered EEG relative power frequencies during the inactive and active phase. Conclusions Both oral nicotine administration and abstinence lead to sleep disturbances in mice. Similarities between this model and human reports on the effect of nicotine/nicotine withdrawal on sleep support its utility in examining the molecular mechanisms that modulate the relationship between sleep, nicotine, and nicotine abstinence/withdrawal.